Exhibit 23.1

The Board of Directors
Unigene Laboratories, Inc.:

We consent to the use of our report  included herein and to the reference to our
firm  under  the  headings  "Selected  Financial  Data"  and  "Experts"  in  the
prospectus.  Our report dated March 17, 2000 contains an  explanatory  paragraph
that states that Unigene  Laboratories,  Inc. has suffered recurring losses from
operations and has a working capital  deficiency which raise  substantial  doubt
about its ability to continue as a going  concern.  The financial  statements do
not  include  any  adjustments  that  might  result  from  the  outcome  of this
uncertainty.


/s/ KPMG LLP


Short Hills, New Jersey
January 19, 2001